Alamar Biosciences Inc Revenue Growth Rates (ALMR), Current and Historic Growth - CSIMarket
CSIMarket
 


Alamar Biosciences Inc   (ALMR)
 

ALMR's Revenue Growth by Quarter and Year

Alamar Biosciences Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ALMR/growth
https://api.csimarket.com/api/v1/companies/ALMR/fundamentals
https://api.csimarket.com/api/v1/companies/ALMR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
ALMR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 33.55
2nd Quarter June 29.43
1st Quarter March 25.46
FY 88.44





ALMR Revenue third quarter 2026 Y/Y Growth Comment
Alamar Biosciences Inc achieved in the third quarter 2026, above Company average Revenue surge of 107.58% year on year, to $ 33.55 millions.

According to the results reported in the third quarter 2026, Alamar Biosciences Inc achieved the best Revenue growth in Laboratory Analytical Instruments industry. While Alamar Biosciences Inc ' s Revenue doubling of 107.58% ranks overall at the positon no. 245 in the third quarter 2026.




ALMR Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 107.58 %
2nd Quarter June 124.83 %
1st Quarter March -
FY   -

Financial Statements
Alamar Biosciences Inc 's third quarter 2026 Revenue $ 33.55 millions ALMR's Income Statement
Alamar Biosciences Inc 's third quarter 2025 Revenue $ 16.16 millions Quarterly ALMR's Income Statement


ALMR Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 13.98 %
2nd Quarter June 15.59 %
1st Quarter March 27.88 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #1
Healthcare Sector #68
Overall #245

Revenue Y/Y Growth Statistics
High Average Low
94.46 % 81.66 % 68.46 %
(Jun 30 2025)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #1
Healthcare Sector #68
Overall #245
Revenue Y/Y Growth Statistics
High Average Low
94.46 % 81.66 % 68.46 %
(Jun 30 2025)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Alamar Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
23.46 % 19.53 % 15.59 %
(Jun 30 2025)  


ALMR's III. Quarter Q/Q Revenue Comment
Alamar Biosciences Inc achieved in the III. Quarter 2026 below company average Revenue rise of 13.98% quarter on quarter, to $ 33.55 millions.

Within Laboratory Analytical Instruments industry only one company achieved higher sequential Revenue growth. While Alamar Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 617.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #2
Healthcare Sector #111
Overall #617
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #2
Healthcare Sector #111
Overall #617
Revenue Q/Q Growth Statistics
High Average Low
23.46 % 19.53 % 15.59 %
(Jun 30 2025)  


ALMR's III. Quarter Q/Q Revenue Comment
Alamar Biosciences Inc achieved in the III. Quarter 2026 below company average Revenue rise of 13.98% quarter on quarter, to $ 33.55 millions.

Within Laboratory Analytical Instruments industry only one company achieved higher sequential Revenue growth. While Alamar Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 617.


Alamar Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)
12 Months Ending 12 Months Ending 12 Months Ending 12 Months Ending
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
In the Mar 31 2026 period, Alamar Biosciences Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Alamar Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Mar 31 2026 period, Alamar Biosciences Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Alamar Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALMR's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions


About Alamar Biosciences Inc Revenue Growth Rates (ALMR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Alamar Biosciences Inc (CIK 2104204).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-445905
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Alamar Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.